#1 Clinical Trials Search in Europe

Mps-106

This article summarizes several clinical trials investigating the use of MPS-106, a component of the cancer vaccine Tedopi (OSE2101), in immunotherapy treatments for various types of cancer. The trials aim to evaluate the safety and efficacy of MPS-106 alone or in combination with other therapies for patients with non-small cell lung cancer, ovarian cancer, pancreatic cancer, and other advanced solid tumors.

Table of Contents

What is MPS-106?

MPS-106 is one of the key components in an experimental cancer treatment called TEDOPI[1]. It is a synthetically manufactured peptide, which is a small protein-like molecule. MPS-106 is part of a group of 10 peptides that make up the TEDOPI cancer vaccine[2].

TEDOPI Cancer Vaccine

TEDOPI is an investigational cancer vaccine being developed by OSE Immunotherapeutics. It is designed to stimulate the immune system to fight cancer cells. The vaccine contains 10 different peptides, including MPS-106, each chosen for its potential to activate the body’s T cells (a type of immune cell) against cancer[1][2].

Diseases Treated

TEDOPI, which includes MPS-106, is being studied for the treatment of several types of cancer:

  • Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer. TEDOPI is being tested in patients with advanced NSCLC who have previously been treated with immunotherapy[1].
  • Ovarian Cancer: TEDOPI is being evaluated as a maintenance treatment for patients with recurrent ovarian cancer after platinum-based chemotherapy[3].
  • Pancreatic Cancer: Studies are ongoing to assess TEDOPI as a maintenance therapy for patients with advanced pancreatic ductal adenocarcinoma[4].

How It Works

TEDOPI, including MPS-106, works by activating the body’s immune system to recognize and attack cancer cells. Here’s a simplified explanation of the process:

  1. The vaccine is given to patients who have a specific protein on their cells called HLA-A2. This protein is important for the immune system to recognize the vaccine[1].
  2. The peptides in TEDOPI, including MPS-106, are designed to mimic parts of cancer cells[2].
  3. When injected, these peptides stimulate the patient’s T cells to recognize and attack cancer cells that have similar features[1][2].
  4. This targeted immune response helps the body fight the cancer more effectively.

Clinical Trials

TEDOPI, which includes MPS-106, is currently being studied in several clinical trials:

  • ARTEMIA Study: This is a phase 3 trial comparing TEDOPI to docetaxel (a chemotherapy drug) in patients with advanced non-small cell lung cancer who have previously been treated with immunotherapy[1].
  • TEDOVA Study: This phase 2 trial is evaluating TEDOPI as a maintenance treatment for patients with ovarian cancer, either alone or in combination with another immunotherapy drug called pembrolizumab[3].
  • TEDOPAM Study: This phase 2 study is looking at TEDOPI in combination with chemotherapy for patients with advanced pancreatic cancer[4].

Administration

TEDOPI, containing MPS-106, is given as an injection under the skin (subcutaneous injection). The exact dosing schedule may vary depending on the specific clinical trial, but typically involves regular injections over a period of several months[1][2][3][4].

Potential Side Effects

As TEDOPI is still in clinical trials, all of its potential side effects are not yet fully known. However, common side effects of cancer vaccines may include:

  • Injection site reactions (redness, swelling, pain)
  • Flu-like symptoms (fever, chills, fatigue)
  • Nausea
  • Muscle or joint pain

It’s important to note that the safety profile of TEDOPI is still being evaluated in ongoing clinical trials. Patients participating in these trials are closely monitored for any adverse effects[1][3][4].

Trial Name Cancer Type Treatment Primary Endpoint
ARTEMIA Metastatic Non-Small Cell Lung Cancer OSE2101 vs. docetaxel Overall Survival
OSE-279 Combination Advanced Solid Tumors or Lymphomas OSE-279 +/- OSE2101 Safety, Tolerability, Anti-tumor Activity
TEDOVA Recurrent Ovarian Cancer OSE2101 +/- pembrolizumab vs. best supportive care Progression-Free Survival
TEDOPAM Pancreatic Ductal Adenocarcinoma OSE2101 + FOLFIRI vs. FOLFIRI alone Overall Survival at 12 months

FAQ

  • What is MPS-106? MPS-106 is one of the active substances in Tedopi (OSE2101), an experimental cancer vaccine being studied for its potential to stimulate the immune system to fight various types of cancer.
  • What types of cancer are being studied with MPS-106? The clinical trials are investigating MPS-106 (as part of Tedopi) in non-small cell lung cancer, ovarian cancer, pancreatic cancer, and other advanced solid tumors.
  • How is MPS-106 administered to patients? MPS-106 is administered as part of the Tedopi vaccine, which is given as a subcutaneous injection or emulsion for injection.
  • What are the main goals of these clinical trials? The main goals are to assess the safety, efficacy, and overall survival benefits of MPS-106 (as part of Tedopi) alone or in combination with other treatments compared to standard therapies.
  • Who is eligible to participate in these clinical trials? Eligibility varies by trial but generally includes adult patients with specific cancer types, adequate organ function, and certain genetic markers like HLA-A2 positive status. Patients must meet other criteria and not have certain exclusions.

Ongoing Clinical Trials on Mps-106

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • MPS-106: One of the active substances in the experimental cancer vaccine Tedopi (OSE2101), being studied for its potential to stimulate the immune system against cancer.
  • Tedopi (OSE2101): An experimental cancer vaccine containing multiple synthetic peptides, including MPS-106, designed to activate T-cells to target and destroy cancer cells.
  • HLA-A2: A specific human leukocyte antigen (HLA) that is important for the immune system's ability to recognize foreign substances. Patients who are HLA-A2 positive may be more likely to respond to certain immunotherapies.
  • NSCLC: Non-small cell lung cancer, a type of lung cancer being studied in some of the clinical trials with MPS-106.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Immune Checkpoint Inhibitor: A type of drug that blocks certain proteins made by immune system cells, such as PD-1, which can help the immune system kill cancer cells.
  • FOLFIRINOX: A combination chemotherapy regimen used to treat pancreatic cancer, consisting of folinic acid, fluorouracil, irinotecan, and oxaliplatin.
  • Sarcopenia: Age-related loss of muscle mass and function, which may affect how patients respond to cancer treatments.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/